Index -
P/E -
EPS (ttm) -1.16
Insider Own 47.11%
Shs Outstand 30.74M
Perf Week -2.78%
Market Cap 295.11M
Forward P/E -
EPS next Y -0.97
Insider Trans -1.61%
Shs Float 17.15M
Perf Month 4.60%
Income -36.24M
PEG -
EPS next Q -0.27
Inst Own 28.73%
Short Float 0.68%
Perf Quarter 43.76%
Sales 0.31M
P/S 951.98
EPS this Y 13.06%
Inst Trans 0.26%
Short Ratio 0.48
Perf Half Y 386.63%
Book/sh 2.21
P/B 4.11
EPS next Y 3.55%
ROA -34.23%
Short Interest 0.12M
Perf Year 135.75%
Cash/sh 1.51
P/C 6.01
EPS next 5Y -
ROE -42.86%
52W Range 1.52 - 10.44
Perf YTD 52.17%
Dividend Est. -
P/FCF -
EPS past 5Y -21.21%
ROI -51.05%
52W High -12.84%
Beta 1.51
Dividend TTM -
Quick Ratio 2.51
Sales past 5Y 109.61%
Gross Margin -379.08%
52W Low 498.68%
ATR (14) 0.74
Dividend Ex-Date -
Current Ratio 2.51
EPS Y/Y TTM 18.61%
Oper. Margin -12980.72%
RSI (14) 51.29
Volatility 9.88% 8.31%
Employees 57
Debt/Eq 0.03
Sales Y/Y TTM 14.18%
Profit Margin -11843.79%
Recom 1.67
Target Price 2.75
Option/Short No / Yes
LT Debt/Eq 0.01
EPS Q/Q 19.70%
Payout -
Rel Volume 3.99
Prev Close 9.46
Sales Surprise -56.24%
EPS Surprise 3.10%
Sales Q/Q -36.92%
Earnings Mar 20 AMC
Avg Volume 239.50K
Price 9.10
SMA20 -1.49%
SMA50 9.22%
SMA200 112.32%
Trades
Volume 954,568
Change -3.81%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-30-22 Downgrade
Citigroup
Buy → Neutral
$18 → $4
Nov-19-21 Initiated
Oppenheimer
Outperform
$19
Oct-15-21 Resumed
Cowen
Outperform
Today 01:32AM
Mar-27-24 01:27AM
Mar-25-24 12:00PM
Mar-21-24 09:57AM
Mar-20-24 08:54PM
05:33PM
Loading…
05:33PM
05:20PM
04:05PM
Mar-12-24 11:40AM
Mar-04-24 08:30AM
Feb-29-24 11:14AM
Dec-11-23 12:00PM
Dec-06-23 01:19PM
08:30AM
Nov-22-23 01:00PM
10:59AM
Loading…
Nov-12-23 10:59AM
Nov-08-23 06:29PM
04:05PM
Oct-25-23 08:30AM
Sep-21-23 08:30AM
Aug-31-23 09:35AM
Aug-30-23 09:35AM
Aug-09-23 05:50PM
04:05PM
Jul-31-23 08:30AM
May-25-23 04:15PM
May-15-23 05:15PM
May-10-23 06:05PM
04:05PM
May-04-23 07:31AM
08:30AM
Loading…
Apr-27-23 08:30AM
Apr-24-23 09:35AM
Mar-27-23 12:00PM
02:27AM
Mar-24-23 06:29AM
Mar-22-23 05:35PM
04:05PM
Mar-09-23 04:05PM
Feb-23-23 04:20PM
Feb-18-23 07:43AM
Feb-15-23 08:30AM
Nov-29-22 08:30AM
Nov-15-22 08:30AM
Nov-09-22 06:15PM
04:05PM
Nov-04-22 04:00PM
Oct-04-22 08:30AM
Sep-22-22 08:30AM
Sep-20-22 07:19AM
Aug-11-22 07:00AM
Aug-10-22 05:55PM
04:05PM
Aug-03-22 10:00AM
Jul-28-22 08:30AM
Jun-06-22 02:15PM
May-19-22 04:15PM
May-18-22 03:03PM
May-10-22 04:05PM
May-05-22 08:30AM
May-02-22 08:30AM
Apr-12-22 08:30AM
Mar-30-22 07:30AM
Mar-29-22 04:00PM
Mar-18-22 12:00PM
07:00AM
Mar-03-22 08:30AM
Feb-17-22 08:30AM
Feb-07-22 08:30AM
Feb-01-22 08:30AM
Dec-15-21 08:30AM
Dec-02-21 08:00AM
Dec-01-21 11:40AM
Nov-30-21 08:00AM
Nov-10-21 09:01AM
Nov-09-21 04:01PM
Nov-08-21 04:20PM
Nov-04-21 08:00AM
Nov-03-21 08:00AM
Nov-02-21 08:00AM
Oct-27-21 08:30AM
Oct-15-21 10:59AM
Sep-28-21 08:30AM
Sep-20-21 08:30AM
Sep-15-21 08:00AM
Sep-14-21 08:00AM
Sep-13-21 08:00AM
Aug-30-21 04:05PM
Aug-17-21 08:00AM
Jul-14-21 09:03PM
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Boniface John J. Chief Scientific Officer Mar 28 '24 Option Exercise 0.91 24,474 22,271 164,245 Mar 28 05:56 PM Boniface John J. Chief Scientific Officer Mar 28 '24 Sale 9.04 24,474 221,245 139,771 Mar 28 05:56 PM Boniface John J. Chief Scientific Officer Mar 27 '24 Option Exercise 0.91 48,909 44,507 188,680 Mar 28 05:56 PM Boniface John J. Chief Scientific Officer Mar 27 '24 Sale 9.62 52,662 506,608 139,771 Mar 28 05:56 PM Lindgardt Zhenya Chief Executive Officer Mar 26 '24 Sale 9.37 38,899 364,484 908,104 Mar 26 08:00 PM Boniface John J. Chief Scientific Officer Mar 26 '24 Sale 9.55 21,438 204,733 143,524 Mar 26 05:38 PM Aerts Austin Chief Financial Officer Mar 26 '24 Sale 9.37 8,092 75,822 322,488 Mar 26 08:00 PM Boniface John J. Chief Scientific Officer Mar 25 '24 Sale 9.10 22,163 201,683 164,962 Mar 26 04:20 PM Harrison Robert Gardner Chief Information Officer Mar 06 '24 Sale 9.02 2,138 19,285 145,697 Mar 07 04:15 PM Jackson Benjamin General Counsel Mar 06 '24 Sale 9.02 1,856 16,741 150,179 Mar 07 04:15 PM Boniface John J. Chief Scientific Officer Mar 06 '24 Sale 9.02 1,664 15,009 187,125 Mar 07 04:16 PM Kearney Paul Chief Data Officer Mar 06 '24 Sale 9.02 1,028 9,273 159,038 Mar 07 04:16 PM Aerts Austin Chief Financial Officer Mar 06 '24 Sale 9.02 444 4,005 330,580 Mar 07 04:16 PM Lindgardt Zhenya Chief Executive Officer Feb 06 '24 Sale 8.03 27,997 224,816 947,003 Feb 07 04:56 PM Aerts Austin Chief Financial Officer Feb 06 '24 Sale 8.03 9,786 78,582 331,024 Feb 07 04:56 PM Boniface John J. Chief Scientific Officer Feb 06 '24 Sale 8.03 5,665 45,490 188,789 Feb 07 04:57 PM Jackson Benjamin General Counsel Feb 06 '24 Sale 8.03 5,665 45,490 152,035 Feb 07 04:57 PM Harrison Robert Gardner Chief Information Officer Feb 06 '24 Sale 8.03 5,665 45,490 147,835 Feb 07 04:56 PM Kearney Paul Chief Data Officer Feb 06 '24 Sale 8.03 4,984 40,022 160,066 Feb 07 04:56 PM Jackson Benjamin General Counsel Dec 07 '23 Sale 5.22 10,000 52,200 157,700 Dec 07 09:35 PM Boniface John J. Chief Scientific Officer Dec 07 '23 Sale 4.80 5,000 24,000 194,454 Dec 07 09:35 PM Harrison Robert Gardner Chief Information Officer Jun 05 '23 Sale 3.23 5,000 16,150 28,500 Jun 06 04:07 PM Kearney Paul Chief Data Officer Apr 06 '23 Option Exercise 0.75 24,050 18,038 40,050 Apr 07 04:14 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite